Hostname: page-component-54dcc4c588-trf7k Total loading time: 0 Render date: 2025-10-13T11:03:41.855Z Has data issue: false hasContentIssue false
  • English
  • Français

A case series and literature review on patients with rhinological complications secondary to the use of cocaine and levamisole

Published online by Cambridge University Press:  20 May 2020

R J Green ,
Q Gardiner ,
K Vinod ,
R Oparka  and
P D Ross
R J Green*
Affiliation:
Department of ENT, Ninewells Hospital and Medical School, Dundee, Scotland, UK
Q Gardiner
Affiliation:
Department of ENT, Ninewells Hospital and Medical School, Dundee, Scotland, UK
K Vinod
Affiliation:
Department of Rheumatology, Ninewells Hospital and Medical School, Dundee, Scotland, UK
R Oparka
Affiliation:
Department of Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, UK
P D Ross
Affiliation:
Department of ENT, Ninewells Hospital and Medical School, Dundee, Scotland, UK
*
Author for correspondence: Mr Richard James Green, ENT Department, Ninewells Hospital, Dundee DD1 9SY, Scotland, UK E-mail: Richard.green14@nhs.net Fax: +44 (0)1382 632816
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Levamisole is an increasingly common cutting agent used with cocaine. Both cocaine and levamisole can have local and systemic effects on patients.

Methods

A retrospective case series was conducted of patients with a cocaine-induced midline destructive lesion or levamisole-induced vasculitis, who presented to a Dundee hospital or the practice of a single surgeon in Paisley, from April 2016 to April 2019. A literature review on the topic was also carried out.

Results

Nine patients from the two centres were identified. One patient appeared to have levamisole-induced vasculitis, with raised proteinase 3, perinuclear antineutrophil cytoplasmic antibodies positivity and arthralgia which improved on systemic steroids. The other eight patients had features of a cocaine-induced midline destructive lesion.

Conclusion

As the use of cocaine increases, ENT surgeons will see more of the complications associated with it. This paper highlights some of the diagnostic issues and proposes a management strategy as a guide to this complex patient group. Often, multidisciplinary management is needed.

Keywords

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNoseDeformitiesCocaineNasal Obstruction

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 134 , Issue 5 , May 2020 , pp. 440 - 446
Copyright
Copyright © The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

Mr R J Green takes responsibility for the integrity of the content of the paper

References

Chung, C, Tumeh, PC, Birnbaum, R, Tan, BH, Sharp, L, McCoy, E et al. Characteristic purpura of the ears, vasculitis, and neutropenia– a potential public health epidemic associated with levamisole-adulterated cocaine. J Am Acad Dermatol 2011;65:722–5CrossRefGoogle ScholarPubMed
Barbano, G, Ginevri, F, Ghiggeri, GM, Gusmano, R. Disseminated autoimmune disease during levamisole treatment of nephrotic syndrome. Pediatr Nephrol 1999;13:602–3CrossRefGoogle ScholarPubMed
Nolan, L, Jen, KY. Pathologic manifestations of levamisole-adulterated cocaine exposure. Diagn Pathol 2015;10:48CrossRefGoogle ScholarPubMed
United Nations Office on Drugs and Crime. World Drug Report 2016. Vienna: United Nations Office on Drugs and Crime, 2016Google Scholar
Scottish Government. Scottish Crime and Justice Survey 2014/15: Drug Use. In: https://www.gov.scot/publications/scottish-crime-justice-survey-2014-15-drug-use/ [12 April 2020]Google Scholar
Morassi, ML, Trimarchi, M, Nicolai, P, Gregorini, G, Maroldi, R, Specks, U et al. Cocaine, ANCA, and Wegener's granulomatosis. Pathologica 2001;93:581–3Google ScholarPubMed
Bradford, M, Rosenberg, B, Moreno, J, Dumyati, G. Bilateral necrosis of earlobes and cheeks: another complication of cocaine contaminated with levamisole. Ann Intern Med 2010;152:758–9CrossRefGoogle ScholarPubMed
Kunzler, D, Lagrimas, L, Vo, T, DeCrescenzo, A, Kaltwasser, K, Wilson, J. Antineutrophil cytoplasmic antibodies negative levamisole-induced leukocytoclastic vasculitis: a presumed case and literature review. Int J Dermatol 2018;57:1411–16CrossRefGoogle ScholarPubMed
Lood, C, Hughes, G. Neutrophil extracellular traps as a potential source of autoantigen in cocaine-associated autoimmunity. Rheumatology (Oxford) 2017;56:638–43Google ScholarPubMed
Trimarchi, M, Bussi, M, Sinico, RA, Meroni, P, Specks, U. Cocaine-induced midline destructive lesions – an autoimmune disease? Autoimmun Rev 2013;12:496–500CrossRefGoogle ScholarPubMed
Trimarchi, M, Gregorini, G, Facchetti, F, Morassi, ML, Manfredini, C, Maroldi, R et al. Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. Medicine (Baltimore) 2001;80:391–404CrossRefGoogle ScholarPubMed
Wiesner, O, Russell, KA, Lee, AS, Jenne, DE, Trimarchi, M, Gregorini, G et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004;50:2954–65CrossRefGoogle Scholar
Subesinghe, S, van Leuven, S, Yalakki, L, Sangle, S, D'Cruz, D. Cocaine and ANCA associated vasculitis-like syndromes – a case series. Autoimmun Rev 2018;17:73–7CrossRefGoogle ScholarPubMed
McGrath, MM, Isakova, T, Rennke, HG, Mottola, AM, Laliberte, KA, Niles, J. Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. J Am Soc Nephrol 2011;6:2799–805CrossRefGoogle ScholarPubMed
Pearson, T, Bremmer, M, Cohen, J, Driscoll, M. Vasculopathy related to cocaine adulterated with levamisole: a review of the literature. Dermatol Online J 2012;18:1Google ScholarPubMed
Marquez, J, Aguirre, L, Muñoz, C, Echeverri, A, Restrepo, M, Pinto, LF. Cocaine-levamisole-induced vasculitis/vasculopathy syndrome. Curr Rheumatol Rep 2017;19:36CrossRefGoogle ScholarPubMed
Czuchlewski, DR, Brackney, M, Ewers, C, Manna, J, Fekrazad, MH, Martinez, A et al. Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine. Am J Clin Pathol 2010;133:466–72CrossRefGoogle ScholarPubMed
Abdul-Karim, R, Ryan, C, Rangel, C, Emmett, M. Levamisole-induced vasculitis. Proc (Bayl Univ Med Cent) 2013;26:163–5CrossRefGoogle ScholarPubMed
Trimarchi, M, Nicolai, P, Lombardi, D, Facchetti, F, Morassi, ML, Maroldi, R. Sinonasal osteocartilaginous necrosis in cocaine abusers: experience in 25 patients. Am J Rhinol 2003;17:33–43CrossRefGoogle ScholarPubMed
Trimarchi, M, Bondi, S, Della Torre, E, Terreni, MR, Bussi, M. Palate perforation differentiates cocaine-induced midline destructive lesions from granulomatosis with polyangiitis. Acta Otorhinolaryngol Ital 2017;37:281–5Google ScholarPubMed
Peikert, T, Finkielman, JD, Hummel, AM, McKenney, ME, Gregorini, G, Trimarchi, M et al. Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. Arthritis Rheum 2008;58:46–51CrossRefGoogle ScholarPubMed
Roberts, JA, Chevez-Barrios, P. Levamisole-induced vasculitis: a characteristic cutaneous vasculitis associated with levamisole adulterated cocaine. Arch Pathol Lab Med 2015;139:1058–61CrossRefGoogle ScholarPubMed
Molteni, M, Saibene, AM, Luciano, K, Maccari, A. Snorting the clivus away: an extreme case of cocaine-induced midline destructive lesion. BMJ Case Rep 2016;2016:bcr2016216393CrossRefGoogle ScholarPubMed
Pope, JD, Drummer, OH, Schneider, HG. The cocaine cutting agent levamisole is frequently detected in cocaine users. Pathology 2018;50:536–9CrossRefGoogle ScholarPubMed
Imbernón-Moya, A, Chico, R, Aguilar-Martínez, A. Cutaneous mucosal manifestations associated with cocaine use [in Spanish]. Med Clin (Barc) 2016;146:544–9CrossRefGoogle Scholar